You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
三葉草生物(02197.HK)擬本年完成新冠候選疫苗加強針開發
阿思達克 02-15 01:52
三葉草生物-B(02197.HK)公布,公司計劃於2022年完成新冠候選疫苗作為通用加強針的開發,以使其在無論基礎免疫接種何種技術疫苗,或是否有既往嚴重急性呼吸系統綜合症冠狀病毒2型「SARS-CoV-2」感染史的情況下,可作為加強針使用。 此外,公司與中國國家藥品監督管理局「NMPA」、歐洲藥品管理局「EMA」及世界衛生組織「WHO」就支持SCB-2019(CpG 10188/鋁佐劑)的附條件申請所需數據保持積極主動的聯絡,並有望在註冊申請中包括加強針的臨床數據。預計於2022年中完成向中國NMPA的註冊申請,並於第三季度完成向WHO及EMA的註冊申請,一旦獲得附條件批准,就啟動產品上市。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account